A phase II trial of paclitaxel and carboplatin in the treatment of hormone-refractory prostate cancer (HRPC).

Trial Profile

A phase II trial of paclitaxel and carboplatin in the treatment of hormone-refractory prostate cancer (HRPC).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Carboplatin; Paclitaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2012 Actual patient numbers amended from 83 to 58 as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Bristol-Myers Squibb trial company and lead trial centre added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top